💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

FACTBOX-Five facts about Roche's new drugs head

Published 09/08/2009, 02:08 AM
Updated 09/08/2009, 02:12 AM
SASY
-

ZURICH, Sept 8 (Reuters) - Roche Holding AG named Pascal Soriot to head its drugs operations, by far its largest business, replacing veteran William Burns who retires at the end of the year.

Here are five facts about the new chief operating officer of Roche's pharmaceuticals unit, which accounts for nearly 80 percent of group sales of 45.6 billion Swiss francs ($43.14 billion):

* Born in 1959, Soriot has French nationality.

* He trained as a veterinary surgeon in France before taking an MBA with a major in finance in Paris and started his career in the pharmaceuticals industry with Roussel.

* Became chief operating officer of Aventis' U.S. operations in 2002, before it became part of Sanofi-Aventis. * Joined Roche in 2006 as head of strategic marketing.

* He is currently CEO of Genentech and has been co-leading, with former Genentech chief Arthur Levinson, the integration team which is designing the future set-up of the combined company. ($1=1.057 Swiss Franc) (Reporting by Sam Cage; editing by Simon Jessop)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.